(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...

Researchers in the U.S. examined time to first hospitalization for hepatic decompensation, liver transplantation, or death in patients with PBC. A separate model tracked time outside of prespecified ...

—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...

Primary biliary cholangitis (PBC) is a rare chronic autoimmune cholangiopathy that mainly affects middle-aged women, ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE ...

Seladelpar is an oral, selective peroxisome proliferator-activated receptor delta agonist. Treatment with seladelpar was associated with an improvement in cholestatis markers in patients with primary ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

Please provide your email address to receive an email when new articles are posted on . International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the ...

Seladelpar, an investigational selective agonist of peroxisome proliferator–activated receptor-delta (PPAR-δ), significantly improves liver biomarkers of disease activity and bothersome symptoms of ...

For patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar have a biochemical response and alkaline phosphatase ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi ® (seladelpar) ...

The European Commission has granted conditional approval for Ipsen's IQIRVO (elafibranor) for the treatment of primary biliary cholangitis in adults, marking the first new therapy for this condition ...